Company profile
Cerus Corporation
NASDAQ: CERS · Healthcare · Medical - Devices
#281 of 1,418 Healthcare companies by revenue62nd-percentile growth
EA Score
74BFH 64DQ 91GM 65SS 80
v0.1 · 65/100 weight · provisional
↑ filing timeliness, listing tenure · ↓ balance-sheet leverage, 3-yr revenue growth
Methodology →Revenue TTM
$222.8M
Rev growth YoY (TTM)
+20.3%
Net income (FY)
-$15.6M
Employees
268
as of 2026-08-11
Market cap
$507.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$233.8M$233.8M2025
Net income-$15.6M-$15.6M2025
Operating income-$8.7M-$8.7M2025
Total assets$221.9M$221.9M2025
Liabilities$156.9M$156.9M2025
Equity$64.2M$64.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product88%
Government Contract12%
By geography
UNITED STATES61%
Other Countries29%
FRANCE10%
The read
What is Cerus Corporation’s revenue?
Cerus Corporation booked $233.8M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a -6.7% net margin.
Peers · Healthcare
OrthoPediatrics Corp.69BAkebia Therapeutics, Inc.66BAnaptysBio, Inc.75B+Talkspace, Inc.71BPuma Biotechnology, Inc.72BAxoGen, Inc.80B+Neighbors
Contra Costa →Key facts
CEOVivek K. Jayaraman
SectorHealthcare
IndustryMedical - Devices
HeadquartersConcord, CA
ExchangeNASDAQ: CERS
Employees268
IPO date1997-01-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.